XML 121 R100.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Oct. 01, 2017 | Jul. 02, 2017 | Apr. 02, 2017 | Jan. 01, 2017 | Oct. 02, 2016 | Jul. 03, 2016 | Apr. 03, 2016 | Dec. 31, 2017 | Jan. 01, 2017 | Jan. 03, 2016
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | $ 20,195 | $ 19,650 | $ 18,839 | $ 17,766 | $ 18,106 | $ 17,820 | $ 18,482 | $ 17,482 | $ 76,450 | $ 71,890 | $ 70,074
Earnings before provision for taxes on income | 2,560 | 4,790 | 4,748 | 5,575 | 4,324 | 5,281 | 4,904 | 5,294 | 17,673 | 19,803 | 19,196
Identifiable Assets | 157,303 |  |  |  | 141,208 |  |  |  | 157,303 | 141,208 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 3,279 | 3,226 | 3,463
Depreciation and Amortization |  |  |  |  |  |  |  |  | 5,642 | 3,754 | 3,746
Consumer |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 3,540 | 3,356 | 3,478 | 3,228 | 3,432 | 3,261 | 3,419 | 3,195 |  |  |
Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 9,681 | $ 9,695 | $ 8,635 | $ 8,245 | 8,232 | $ 8,400 | $ 8,654 | $ 8,178 |  |  |
Operating Segments |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 129,893 |  |  |  | 91,221 |  |  |  | 129,893 | 91,221 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 2,987 | 2,885 | 3,238
Depreciation and Amortization |  |  |  |  |  |  |  |  | 5,306 | 3,422 | 3,433
Corporate, Non-Segment |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments |  |  |  |  |  |  |  |  | 1,326 | 1,043 | 1,151
Corporate, Non-Segment | General Corporate |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 27,410 |  |  |  | 49,987 |  |  |  | 27,410 | 49,987 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 292 | 341 | 225
Depreciation and Amortization |  |  |  |  |  |  |  |  | 336 | 332 | 313
Operating Segments |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 76,450 | 71,890 | 70,074
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 18,999 | 20,846 | 20,347
Operating Segments | United States |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 39,863 | 37,811 | 35,687
Operating Segments | Consumer |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 13,602 | 13,307 | 13,507
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 2,524 | 2,441 | 1,787
Identifiable Assets | 25,030 |  |  |  | 23,971 |  |  |  | 25,030 | 23,971 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 485 | 486 | 544
Depreciation and Amortization |  |  |  |  |  |  |  |  | 674 | 608 | 559
Operating Segments | Consumer | United States |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 5,565 | 5,420 | 5,222
Operating Segments | Consumer | International |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 8,037 | 7,887 | 8,285
Operating Segments | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 36,256 | 33,464 | 31,430
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 11,083 | 12,827 | 11,734
Identifiable Assets | 59,450 |  |  |  | 27,477 |  |  |  | 59,450 | 27,477 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 936 | 927 | 1,063
Depreciation and Amortization |  |  |  |  |  |  |  |  | 2,416 | 886 | 929
Operating Segments | Pharmaceutical | United States |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 21,474 | 20,125 | 18,333
Operating Segments | Pharmaceutical | International |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 14,782 | 13,339 | 13,097
Operating Segments | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 26,592 | 25,119 | 25,137
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 5,392 | 5,578 | 6,826
Identifiable Assets | $ 45,413 |  |  |  | $ 39,773 |  |  |  | 45,413 | 39,773 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 1,566 | 1,472 | 1,631
Depreciation and Amortization |  |  |  |  |  |  |  |  | 2,216 | 1,928 | 1,945
Operating Segments | Medical Devices | United States |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | 12,824 | 12,266 | 12,132
Operating Segments | Medical Devices | International |  |  |  |  |  |  |  |  |  |  |
Sales by segment of business |  |  |  |  |  |  |  |  |  |  |
Total |  |  |  |  |  |  |  |  | $ 13,768 | $ 12,853 | $ 13,005

X
- Definition Expense not allocated to segments. + References No definition available. + Details
Name: | jnj_ExpenseNotAllocatedToSegments
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=jnj_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |